H.C. Wainwright keeps USD 15.00 target for ImmunityBio stock

Published on 10/24/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are set for November 3, 2026, with USD 51.24 million in second-quarter revenue. ImmunityBio stock costs EUR 7.36 on October 24, 2026.

Analyst target and reporting date

On October 15, 2026, H.C. Wainwright kept a USD 15.00 target for ImmunityBio.
Second-quarter revenue reached USD 51.24 million against a USD 49.70 million consensus estimate.
ImmunityBio stock costs EUR 7.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio (US45256X1037) stock is priced at EUR 7.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. H.C. Wainwright kept a Strong Buy rating and raised its price target from USD 10.00 to USD 15.00 in a note dated October 15, 2026, according to Zacks.

Target stands above the Nasdaq price

The USD 15.00 target is 82.48 percent above ImmunityBio's USD 8.22 Nasdaq price from October 23, 2026. Zacks listed four short-term analyst targets ranging from USD 12.00 to USD 16.00, with an average of USD 14.25, but those figures reflect a small analyst sample.

The latest operating comparison is more concrete. MarketBeat reported second-quarter revenue of USD 51.24 million against a USD 49.70 million consensus estimate, a 3.10 percent revenue beat. The company also posted a GAAP loss of USD 0.22 per share versus a consensus loss of USD 0.08.

Stock remains below its yearly high

ImmunityBio's Nasdaq price of USD 8.22 on October 23, 2026 stood 33.87 percent below the 52-week high of USD 12.43 and 321.54 percent above the 52-week low of USD 1.95. The same session's volume was 5,922,752 shares, compared with an average daily volume of 20,521,498 shares cited by MarketBeat.

November results are the next date

ImmunityBio is scheduled to report its next results on November 3, 2026. The company also said on October 21, 2026 that it had completed database lock for Cohort A of the 366-patient QUILT-2.005 trial, with topline results expected in November, as reported by StockTitan.

The October 16, 2026 release on QUILT-3.032 reported a 71.00 percent complete-response rate and 84.00 percent cystectomy-free survival at 36 months among responders. ImmunityBio also reported responses extending beyond 53 months, although the company warned that delayed cystectomy can carry serious risks for patients with persistent high-grade disease.

What the numbers mean for investors

The market picture combines a large analyst target gap with a recent quarterly revenue beat and a substantial distance from the yearly high. The next results date should provide the next dated test of revenue growth, losses and progress toward broader ANKTIVA use.

EUR 7.36 price indication

ImmunityBio was trading at EUR 7.36 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The primary Nasdaq quote was USD 8.22 on October 23, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of ImmunityBio stock.